Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm neutral on OPT stock.

is pleased to announce that its lead compound (RSBT-001) reduced inflammatory biomarkers and mediators of fibrosis in a human precision cut lung slices study. RSBT-001 was evaluated in three ...